Indication
Nodular
1 clinical trial
2 products
3 drugs
Clinical trial
A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk NeuroblastomaStatus: Active (not recruiting), Estimated PCD: 2023-06-30
Drug
DinutuximabDrug
FOLFOXIRIProduct
IsotretinoinDrug
GM-CSFProduct
TMZ